Foolish Choices Cost Lives and Money

Jun 09 2011 Published by under MedicoLegal Concerns

Click for source

The June 9 issue of New England Journal of Medicine includes a Perspective piece from a nephrologist and hospitalist at the county hospital in Houston, TX. They discuss an issue well-known to those of us in the nephrology community, the care of illegal immigrants with kidney failure. Kidney disease strikes a disproportionate number of ethnic minorities, including those of African, Hispanic, and Native American Ancestry.

US citizens qualify for public funding for their dialysis and transplants, either through the Medicare or Medicaid programs. Federal law prohibits the use of federal funds for non-emergency services for undocumented residents. Raghavan and Nuila describe the plight of these people:

Santiago is in the ER again. He sits in a special row of 20 patients, all of whom are waiting for one result: the potassium. Is it high enough today? Two days ago he was here, and it was only 6 meq per liter. We discharged him. Right now his chest hurts, and he is short of breath. Nothing new, and Santiago knows that if he's to be dialyzed today, these symptoms don't matter. Only the potassium matters.

Thrice weekly hemodialysis, the current standard-of-care for citizens, costs $72,000 per patient per year. Some would argue that this regimen is inadequate, that we should be providing more dialysis to improve patient outcomes, but many of these patients can work and live reasonable lives. Emergency dialysis for undocumented residents places the lives of these people at risk, as well as resulting in ER visits and hospitalizations for emergencies that must be paid for by our public hospitals (using local and state tax dollars and subsidized by increasing charges to other patients). Total costs average $200,000 annually for each of these emergency-dialysis patients.

My direct experience deals with the children without papers, who came to this country with their parents. Sometimes the families can save and fund-raise and get their children transplanted, although then they must bear the burden of the costs of immunosuppression for the rest of their lives. Sometimes good parents allow their children to become wards of the state so they can get the medical care that will give them better lives.

The examples that Raghavan and Nuila provide illustrate the problems of current policy. People who came to this country illegally, but to work hard to support families, can no longer work because of the inadequate care they receive for their conditions. This inadequate care not only prevents them from contributing to the economy via their work, purchases, and sales taxes, but ends up costing the public more than if we provided standard in-center dialysis. The authors admit that this issue "lies at the intersection of debates over the soaring cost of health care and the need for immigration reform."

Do we have an ethical duty to provide the same standard of care for all sick patients within our borders? Or would mandating the providion of health care (and of maintenance-dialysis treatments) create an incentive for illegal immigration and worsen the current situation?

There is no easy solution. But with this particular disease, there are cheaper, more compassionate alternatives...

They make an excellent case for the foolishness of our current choices. Should we let these people die of their disease? Should we continue to provide our current torture care at almost 3 times the cost of standard care? Or can we come up with a more effective and cost-effective scheme for dealing with this problem?

Note: This article is not live on the NEJM site as I schedule this post; I will add a direct link to the text later on June 9. And that link is now live.

Share

No responses yet

Giving Thanks for Urine

Nov 23 2010 Published by under [Etc]

Last week I traveled to Denver for the Annual Meeting of the American Society of Nephrology, also known as RenalWeek. While there, I read an article in The Atlantic: "God Help You, You're on Dialysis," by Robin Fields of Propublica. The introductory excerpt:

Edel Rodriguez from the original article

Every year, more than 100,000 Americans start dialysis. One in four of them will die within 12 months—a fatality rate that is one of the worst in the industrialized world. Oh, and dialysis arguably costs more here than anywhere else. Although taxpayers cover most of the bill, the government has kept confidential clinic data that could help patients make better decisions. How did our first foray into near-universal coverage, begun four decades ago with such great hope, turn out this way? And what lessons does it hold for the future of health-care reform?

The article (and the extended version at Propublica) provide a scary view of the US end-stage renal disease program. Each dialysis treatment costs more in the US than in other industrialized countries, yet our patients suffer worse outcomes while on standard dialysis.

My personal perspective is a bit more optimistic; as a pediatric nephrologist, I am dealing with younger, healthier patients who usually get transplanted from a relative in a few months. If no living donor proves compatible, we usually pursue home peritoneal dialysis every night as the treatment of choice. In the adult world, the most common option is in-center hemodialysis for 3 sessions each week. From the standpoint of biochemical balance, each session should be 4 hours, although the justification for this schedule has more to do with resources than with outcomes. Many centers allow patients to run less time. Patients hate being tied to a machine for long hours, and the centers can then get the station ready for another patient. Economies of scale allow dialysis units to operate at a profit.

Perhaps giving patients more choice in their treatment options and letting market forces run wild is not the best way to provide health care. But I digress...

Kidneys control a number of bodily functions. In addition to fluid and chemical balance, they produce the active form of vitamin D; kidney failure causes significant bone issues without careful management. The kidney also produces erythropoietin, a hormone that tells the bone marrow to make red blood cells which carry oxygen to the body. When the kidneys fail, anemia can occur.

Dialysis and transplant are therapies that can extend life, but they are not cures for kidney failure. Nothing replaces the kidney quite like the original kidney.

That's why on Thanksgiving, I give thanks that I can pee. If I couldn't, the day would not be the same.

Share

One response so far

Why Kidneys Are Smarter Than Nephrologists

Sep 01 2010 Published by under [Medicine&Pharma]

Two posts over on Stream of Thought show why the kidneys do a much better job adjusting the body's chemical balance than kidney specialists do.

Basic Hemodialysis

How Kidneys Work illustrates the way the kidney first removes virtually everything in solution from the blood and then reabsorbs the 99% of the filtrate that it needs to stay balanced.

Today's post show how nephrologists, using two simple principles of general chemistry, attempt to replace kidney function- and achieve 10-15% of the clearance of these glorious organs.

Click on over; you get to see my video demonstrating diffusion and convection! Bring popcorn!

Share

Comments are off for this post

Heavy Metal

Aug 22 2010 Published by under [Medicine&Pharma]

Once upon a time in nephrology, iron killed people. Today, it seems patients with kidney disease cannot get enough.

Iron marches on

What changed?

1950-1989

As dialysis became the standard of care for patients with end-stage kidney failure, it soon became obvious that the kidney was important in maintaining red blood cell mass in the body. Erythrocytes or red blood cells carry oxygen to the tissues; when lacking, patients have anemia. The kidneys provide most of the erythropoeitin in the body, the hormone that tells the bone marrow to make erythrocytes.

While dialysis kept patients with kidney failure alive, it could not produce erythropoeitin. Patients required periodic transfusions to avoid severe anemia. Soon it became clear that these infusions of red blood cells were also problematic. Many patients had a build-up of iron in various organs. Hemosiderosis could produce life-threatening toxicities in the heart and liver. To avoid these fatal complications, transfusions were withheld until hemoglobin levels fell quite low, to less than 8 g/dL (lower limit of normal 12-13 usually). If dangerous levels of iron accumulated, agents could be used to chemically bind and attempt to clear the iron with dialysis.

The Science of EPO

Work in the 1970s suggested that the kidneys made a hormone that controlled red blood cell production. The molecular structure of erythropoeitin (EPO) was eventually ascertained, and by 1985 production of the recombinant human hormone was underway. It received FDA approval for the treatment of anemia of end-stage renal disease in 1989.

1989-present

A PubMed search shows that from 1950-1988 there were 702 publications when the terms "iron" and "dialysis" are searched. These focused on treatment of iron overload and various regimens for chelation therapy. When these same terms are searched from 1989 through the present, 2004 articles are found which focus on achieving adequate iron stores.

The majority of patients on chronic dialysis receive hemodialysis, in which blood is run through a pump-driven filter and returned to the body. Small amounts of blood are lost each time a treatment occurs, generally 3 times each week. Once EPO became available, this blood loss became critical. Patients often did not have the stores of iron to respond to EPO. Giving sufficient oral iron to overcome these losses is often impossible; gastrointestinal symptoms and interactions with other drugs get in the way.

Transfusion would be one way to get iron in intravenously; however, then the patient is exposed to the risks of blood. Intravenous iron preparations were dusted off for a new market. Iron cannot be given parenterally; the toxic iron molecule must be coated by a carbohydrate of some sort to prevent fatal toxicity. A number of preparations are on the market, with more on the way.

Clinical Guidelines

Anemia treatment guidelines for chronic kidney disease are undergoing revision; the new statement should be available in 2011.

For now, target hemoglobin levels are 11-13 g/dL; higher levels have been associated with excessive cardiovascular mortality. Transferrin saturation levels should be >20% for all dialysis patients, and ferritin levels should be >100 ng/mL for peritoneal dialysis patients who have minimal ongoing blood loss. Hemodialysis patients should have ferritin levels >200  but <500 ng/mL to allow optimal response to EPO.

Personal Thoughts

I began my nephrology training in 1988, just before the approval of EPO. I saw the ravages of iron overload in my patients. Then EPO came along, and we could not only treat anemia without life-threatening complications, but we could also normalize hemoglobin levels. Patients felt much better, even though most claimed to "feel fine" at hemoglobin levels of 8 or 9.

I never imagined the volume of ads I would eventually see for iron products in my journals. The story of iron provides further proof that physicians have to remain life-long students, able to adjust to the changing body of medical knowledge.

Image courtesy of PhotoXpress.

Share

One response so far

Bad Behavior has blocked 364 access attempts in the last 7 days.